D933QC00001

Research code: D933QC00001
Research name: Randomised, double-blind, placebo-controlled, multicentre, international phase III research evaluating the use of durvalumab or durvalumab in combination with tremelimumab as consolidation treatment in patients with limited small cell lung cancer who have not progressed after concurrent chemoradiotherapy (ADRIATIC).
Indication: lung cancer
Principal researcher: Ewa Chmielowska, MD, PhD